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Abstract: Complement overactivation has been reported in most patients with Barraquer–Simons
syndrome (BSS), a rare form of acquired partial lipodystrophy. Complement Factor D (FD) is a serine
protease with a crucial role in the activation of the alternative pathway of the complement system,
which is mainly synthesized by adipose tissue. However, its role in the pathogenesis of BSS has
not been addressed. In this study, plasma FD concentration was measured in 13 patients with BSS,
20 patients with acquired generalized lipodystrophy, 22 patients with C3 glomerulopathy (C3G),
and 50 healthy controls. Gene expression and immunohistochemistry studies were assayed using
atrophied adipose tissue from a patient with BSS. We found significantly elevated FD levels in BSS
cases compared with the remaining cohorts (p < 0.001). There were no significant differences in
FD levels between sexes but FD was strongly and directly associated with age in BSS (r = 0.7593,
p = 0.0036). A positive correlation between FD and C3 was seen in patients with C3G, characterized
by decreased FD levels due to chronic C3 consumption, but no correlation was detected for BSS.
Following mRNA quantification in the patient’s adipose tissue, we observed decreased CFD and C3
but elevated C5 transcript levels. In contrast, the increased FD staining detected in the atrophied
areas reflects the effects of persistent tissue damage on the adipose tissue, thus providing information
on the ongoing pathogenic process. Our results suggest that FD could be a reliable diagnostic
biomarker involved in the pathophysiology of BSS by promoting unrestrained local complement
system activation in the adipose tissue environment.
Keywords: adipsin; complement factor D; acquired partial lipodystrophy; Barraquer–Simons syn-
drome; complement system
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1. Introduction
Lipodystrophies are a heterogeneous group of rare disorders characterized by the
loss of adipose tissue [1]. There are multiple subtypes of lipodystrophies, which can
be congenital or acquired and which in turn vary in the distribution of adipose tissue
loss, being partial, generalized, or localized. One of these diseases is Barraquer–Simons
syndrome (BSS; ORPHA:79087), an acquired form of partial lipodystrophy characterized by
bilateral symmetrical loss of adipose tissue at upper body locations [1]. Dysregulation of the
alternative pathway (AP) of the complement system, denoted by C3 hypocomplementemia,
is a frequent clinical feature among patients with BSS, commonly due to the presence of C3
nephritic factor (C3NeF) [2]. C3NeF is an autoantibody directed to the AP C3 convertase
that acts by stabilizing and increasing the half-life of the complex, which leads to C3
consumption and chronic C3 hypocomplementemia [3]. In most of the published cohorts
of patients with BSS, C3NeF is the most frequent antibody (70%) [2,4], although our group
has described the existence of additional autoantibodies against AP proteins [2]. Moreover,
Mathieson et al. evidenced that C3NeF could lyse adipocytes [5].
C3NeF is not exclusive to patients with BSS, but is also involved in another patho-
logical condition not related to lipodystrophy called C3 glomerulopathy (C3G) [6]. The
mechanistic connection with complement activation is further reinforced by the fact that
20% of BSS patients eventually develop C3G [1]. Our group has recently published the
first evidence of ongoing complement system activation in affected adipose tissue from
an 11-year-old girl with BSS [7]. This finding, together with the abnormal levels of the AP
proteins in patients with BSS, points to complement dysregulation as a central pathological
event in the development of this rare disease; however, the exact mechanism by which
complement causes fat loss remains unclear.
Complement factor D (FD), also termed adipsin, is a serine protease with a crucial
role in the activation of the AP of the complement system [8,9]. FD is secreted by several
tissues and cell types, although the major source in humans is mature adipocytes and
macrophages in adipose tissue [8–10]. Given the connection of FD with adipose tissue and
complement system activation, it could be considered a central player in the pathogenesis
of BSS, as previously suggested by other authors [4,5,11]. However, this assumption has not
been demonstrated yet. In pathological situations where adipose tissue function is widely
affected, such as lipodystrophy syndromes, the synthesis and secretion of the adipokines
leptin and adiponectin are seriously impaired [1], but this is unknown for FD. Recently,
Wu and collaborators showed that FD levels were reduced but still detected in patients
with congenital and acquired generalized lipodystrophy (CGL and AGL, respectively), in
contrast to patients with familial partial lipodystrophy (FPLD), in whom FD levels were
similar to healthy subjects [12]. However, the authors did not quantify FD levels in patients
with BSS nor did they analyze the existence of local differences in its expression levels and,
therefore, the role of FD in the pathogenesis of the BSS remains unanswered.
The present study aimed to quantify FD levels in a cohort of 13 patients with BSS and
compare them with patients in other pathological situations, such as AGL and C3G, and
with healthy donors. Another objective of this study was to explore the effect of age and
sex on FD levels in the previously mentioned cohorts. Finally, gene expression studies
and detection of FD were carried out on adipose tissue from a patient with BSS previously
studied by our group.
2. Results
2.1. Circulating FD Levels Are Increased in Patients with BSS
The plasma FD concentration was measured in 13 patients with BSS, 20 patients with
AGL, 22 patients with C3G and 50 healthy donors. FD levels were significantly elevated
in patients with BSS compared with individuals from the control, AGL and C3G cohorts
(BSS: median 1.530 µg/mL (IQR—1.425–1.940); controls: 1.185 µg/mL (1.025–1.423); AGL:
0.905 µg/mL (0.753–1.125); C3G: 1.115 µg/mL (0.705–1.570); p < 0.05 for controls and C3G,
and p < 0.001 for AGL) (Figure 1). In contrast, plasma FD levels in the AGL cohort were
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significantly lower than those of controls (p < 0.05) (Figure 1). We performed a Western
blot on the plasma from controls, patients with BSS, C3G and AGL and observed that
FD levels were reduced in patients with AGL and elevated in BSS compared to controls.
Demographic details and basic clinical information are listed in Table 1.
Figure 1. Plasma FD levels. (A) FD levels were quantified in plasma samples from controls (n = 50),
patients with Barraquer–Simons syndrome (BSS, n = 13), patients with C3 glomerulopathy (C3G,
n = 22), and patients with acquired generalized lipodystrophy (AGL, n = 20). The results are presented
as medians and interquartile ranges. Differences between groups were assessed by the Kruskall–
Wallis test. p < 0.05 was considered statistically significant. (B) FD levels were assessed by Western
blot, confirming that FD was elevated in patients with BSS and decreased in patients with AGL.


















Controls (n = 50) 80% 29.88 (6–66) 112.65 None None NA NA NA
BSS (n = 13) 85% 33.69 (11–76) 63.75 69.23 69.23 23.07 Upper body None
C3G (n = 22) 77% 26.2 (7–76) 47.8 72.72 68.18 100 None NA
AGL (n = 20) 80% 27 (6–68) 104.56 None None None Whole body None
Abbreviations: BSS, Barraquer–Simons syndrome; C3G, C3 glomerulopathy; AGL, acquired generalized lipodystrophy; n, number of
individuals; C3NeF, C3 nephritic factor; NA, not applicable. * Normal range for C3 levels were 75–135 mg/dL. ¥ Findings from the genetic
screening of pathogenic variants associated to generalized (AGPAT2, BSCL2, CAV1, PTRF, PPARG) and partial forms (LMNA, PPARG,
PLIN1, CIDEC, LIPE, CAV1, AKT2).
2.2. FD Levels Are a Potentially Reliable Biomarker for the Diagnosis of BSS
A ROC curve using FD levels was implemented to find a cut-off value for predicting
the utility of this parameter as a diagnostic biomarker. ROC curve analysis indicated
that plasma FD levels were a potential diagnostic biomarker for BSS and AGL, with
Area Under the Curve (AUC) values of 0.83 (95% confidence interval (CI): 0.70–0.95,
p < 0.001) (Figure 2A) and 0.75 (0.61–0.89, p < 0.001) (Figure 2B), respectively. In contrast,
in patients with C3G, FD levels were not a reliable biomarker, with an AUC value of
0.54 (0.37–0.71, p = 0.54) (Figure 2C). The cut-off was chosen using the Youden index. An
FD level value ≥1.47 µg/mL was associated with a higher probability to detect patients
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with BSS (sensitivity: 77%, specificity: 78%, negative predictive value: 77%, positive
predictive value: 78%, likelihood ratio: 3.47). However, the validation of the cut-off value
≤0.92 µg/mL for patients with AGL did not show acceptable results (sensitivity: 15%,
specificity: 33%, negative predictive value: 45%, positive predictive value: 10%, likelihood
ratio: 0.23).
Figure 2. Plasma FD levels ROC curves for samples from patients with Barraquer–Simons syndrome (BSS) (A), patients with
acquired generalized lipodystrophy (AGL) (B), and patients with C3 glomerulopathy (C3G) (C). p < 0.05 was considered
statistically significant. AUC, area under the ROC curve.
2.3. Age- and Sex-Related Differences in FD Levels
We analyzed the effect of age on the concentration of FD in all cohorts. Linear
regression analyses demonstrated a significant age-related effect for FD levels in controls,
BSS and C3G cohorts, but not for patients with AGL. Age was significantly and positively
correlated with FD levels in healthy controls (r = 0.2962, p = 0.0368, Figure 3A), patients
with BSS (r = 0.7593, p = 0.0036, Figure 3B) and patients with C3G (r = 0.4782, p = 0.0244,
Figure 3C), but not in patients with AGL (Figure 3D). No significant differences were
observed in FD levels between males and females in all cohorts (Figure 4A–D).
2.4. Effects of Complement System Activation on Plasma FD Levels
To better understand the differences seen in FD levels between patients with BSS
and patients with C3G, we assessed the correlation between circulating C3 and FD lev-
els. Our results showed that FD correlated significantly with C3 in patients with C3G
(r = 0.5863, p = 0.0041), while no correlation was observed in patients with BSS and controls
(Figure 5A–C). In addition, we studied the relationship between C3 levels and age, and no
correlation was observed in any cohort (Figure 5D–F). We then compared FD levels between
patients with positive/negative results for C3NeF autoantibodies in both the BSS and C3G
cohorts. Patients with a positive result for C3NeF had significantly lower serum C3 levels
in both cohorts (p < 0.001) (Figure 6A), although differences in FD concentration were
found only in patients with C3G, being lower in those with C3NeF autoantibodies (C3NeF
positive: 1.080 µg/mL (0.650–1.230), and C3NeF negative: 1.870 µg/mL (1.170–2.220);
p < 0.001; Figure 6B).
2.5. Increased FD Labelling at Lipoatrophic Areas
We performed an immunohistochemistry assay to analyze the presence and localiza-
tion of FD in the adipose tissue from an 11-year-old girl with BSS and two healthy donors
(a 69-year-old male and a 57-year-old female). We observed that FD was overrepresented
and widely extended along affected areas of adipose tissue from the patient with BSS
(Figure 7A) compared with adipose tissue from a healthy donor, in which FD was observed
in small isolated spots (Figure 7B). Using a higher magnification image, we detected that,
although most FD staining was present in the extracellular space and the stroma vascu-
lar cells, there were at least some adipocytes that show remarkable cytoplasmic staining
(Figure 7C). To determine whether the results were due to nonspecific binding of the
primary antibody, we performed isotype control staining (Figure 7D). This result prompted
Int. J. Mol. Sci. 2021, 22, 6608 5 of 14
us to perform gene expression analyses in the same adipose tissue biopsies. Levels of
transcripts corresponding to components of the complement system C3 and Complement
Factor D (CFD) showed reduced expression in adipose tissue from the patient with respect
to healthy controls; in contrast, C5 mRNA was marginally increased (Table 2). Furthermore,
the examination of gene expression levels of master regulatory factors associated with the
promotion of adipogenesis indicated that peroxisome proliferator-activated-γ (PPARG) and
CCAAT/enhancer-binding protein α (CEBPA) mRNAs were down-regulated in the patient
with BSS with respect to controls (Table 2).
Figure 3. Correlation of plasma FD levels with age. Age positively correlated with FD levels from
controls (A), patients with Barraquer–Simons syndrome (BSS) (B), patients with C3 glomerulopathy
(C3G) (C), but not in patients with acquired generalized lipodystrophy (AGL) (D). These correlations
were calculated using the Spearman Rank correlation coefficient. Females are indicated by circles
and males by triangles. p < 0.05 was considered to be statistically significant.
Table 2. mRNA expression levels of genes of the complement system and adipogenesis pathway in subcutaneous adipose
tissue samples from a patient with Barraquer–Simons syndrome and healthy controls.
C3 C5 CFD PPARG CEBPA
Female Barraquer–Simons syndrome (arm, n = 1) 56.9 0.95 99.3 10.1 10.9
Female control (arm, n = 1) 84.8 0.67 194.0 36.5 37.7
Male control (arm, n = 1) 116.0 0.40 100.3 51.0 58.2
Values of mRNA expression in adipose tissue from healthy controls are expressed as the ratio of relative abundance of the mRNA of the
gene of interest relative to 18S rRNA (×10−6). Abbreviations: n, number of individuals; CFD, Complement Factor D; PPARG, Peroxisome
proliferator-activated receptor-γ; CEBPA, CCAAT/enhancer-binding protein-α.
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Figure 4. Differences in plasma FD levels between sexes. FD levels were compared between males
and females in controls (A), patients with Barraquer–Simons syndrome (BSS) (B), patients with C3
glomerulopathy (C3G) (C), and patients with acquired generalized lipodystrophy (AGL) (D). These
comparisons were assessed using the Mann–Whitney test. The results are represented as medians
and interquartile ranges. p < 0.05 was considered to be statistically significant.
Figure 5. Correlation between C3 and FD levels in plasma and between C3 levels and age. The relationship between these
parameters was investigated in controls (A,D), patients with Barraquer–Simons syndrome (BSS) (B,E) and patients with C3
glomerulopathy (C3G) (C,F). Correlations were analyzed using the Spearman Rank correlation coefficient. Females are
indicated by circles and males by triangles. p < 0.05 was considered to be statistically significant.
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Figure 6. Differences in C3 and FD plasma levels in patients with Barraquer–Simons syndrome (BSS)
and patients with C3 glomerulopathy (C3G). C3 (A) and FD (B) levels were analyzed in the BSS and
C3G cohorts according to the presence of C3 nephritic factor (C3NeF). The results are represented as
medians and interquartile ranges. p < 0.05 was considered to be statistically significant.
Figure 7. Immunostaining of FD in adipose tissue. The subcutaneous adipose tissue of a patient with
Barraquer–Simons syndrome (A) showed higher and widely spread staining of FD in comparison
with healthy control tissue (B) (immunohistochemistry, original magnification ×20). More detailed
images from atrophied areas showed that FD staining was detected both in the stroma vascular
fraction and in adipocytes (C) (immunohistochemistry, original magnification ×40). Staining was
performed using a rabbit IgG (ab172730; Abcam) as an isotype control (D) (immunohistochemistry,
original magnification ×40). Scale bars: 100 µm.
3. Discussion
In this study, we found that plasma FD levels are significantly higher in a representa-
tive cohort of patients with BSS compared with controls and another two cohorts composed
of patients with AGL and C3G. This study points to FD as a potential biomarker in BSS.
At the end of the 1980s and the beginning of the 1990s, Dr. Spiegelman’s group
showed that mouse adipocytes secreted a tissue-specific adipokine that they called adipsin,
which has important functions for the development of adipose tissue [9]. This protein
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was found to be identical to human FD, which is considered to be a rate-limiting factor
in the activation of the AP of the complement system [9]. In this pathway, FD cleaves
complement factor B and catalyzes the formation of C3 convertase (C3bBb) [13], which
leads to a proteolytic cascade that produces several complement fragments, including
C3a, C3b, C5a, and C5b, and eventually leads to the formation of the membrane attack
complex (C5b-9) [13].
The role of the complement system in the biology of adipose tissue has been described
in several papers [14–16]. The fact that FD is the only protein of the complement system
that is mainly synthesized by adipocytes, in contrast to the other complement components,
which are produced by the liver, places FD as an important player in adipose tissue function.
Adipocytes are also capable of synthesizing other complement components, particularly
those involved in the initial steps of complement activation (e.g., factors B, C2, C3, C4, C1Q,
C1R, C1S) but they express almost none of the terminal complex components (C8A, C8B,
C8G, C9), with the exception of C5, C6, and C7 [17–20]. Furthermore, local complement
activation promotes lipid accumulation and adipocyte differentiation [21].
Increased levels of serum FD are closely related to several pathological conditions. For
example, plasma FD has been found to be elevated in patients with obesity [22–24], age-
macular degeneration [25], coronary artery disease [26], osteoarthritis [27], non-alcoholic
fatty liver disease [28], and polycystic ovary syndrome [29]. Conversely, according to
different experimental and clinical studies, plasma FD concentrations are low in animals
and patients with diabetes mellitus [30–33], and in those pathological conditions where
adipose tissue is almost completely absent, such as CGL and AGL [12], in agreement
with the results from our group (Figure 1). On the other hand, plasma FD concentrations
were reported to be normal in patients with FPLD, in whom some adipose tissue is pre-
served [12]. Herein, we provide experimental evidence for altered FD plasma levels in
patients with BSS and C3G, two conditions characterized by dysregulation of the AP of the
complement system. Interestingly, while BSS patients exhibited significantly elevated FD
concentrations, those with C3G showed a slight decrease in plasma FD (Figure 1). Addi-
tionally, our results suggest that FD levels may be a marker to identify patients with BSS
(Figure 2A). Specifically, FD levels ≥1.47 µg/mL were associated with a higher probability
of detecting patients with BSS. In contrast, FD levels were not a useful biomarker in patients
with AGL (Figure 2B), which is consistent with the low FD levels typically found in all
generalized lipodystrophies.
Moreover, we observed a significant direct correlation of FD levels with age in healthy
controls, BSS patients and C3G patients, with this correlation being stronger in the BSS
cohort (Figure 3A–C). In striking contrast to this observation, the complete absence of
adipose tissue that characterizes AGL could help explain the lack of age-dependence of FD
levels in patients with this generalized form of lipodystrophy (Figure 3D). Additionally,
no noticeable effect of sex on FD levels in the control, BSS and C3G cohorts was observed
(Figure 4A–D).
FD is constitutively secreted at high rates by adipose tissue but rapidly catabolized in
the proximal renal tubules [9,34]. The fractional catabolic rate of plasma FD has been esti-
mated to be 60% per hour, contributing to its low serum concentrations in non-pathological
situations [35]. Serum FD levels were found to be elevated in patients with chronic renal
failure due to a lower renal catabolic rate [35–37]. In this work, we did not observe differ-
ences in FD concentrations between patients with C3G and controls (Figure 1); however, a
positive correlation between FD and C3 was seen in patients with C3G, a condition char-
acterized by decreased FD levels due to chronic C3 consumption (Figure 5). Surprisingly,
no such FD/C3 correlation was detected in BSS, a clinical condition also characterized by
complement hyperactivation (Figure 5). When we analyzed FD in situations of complement
dysregulation, such as in the presence of C3NeF, plasma FD was significantly lower in
C3NeF-positive patients with C3G compared with the rest of the negative individuals
(Figure 6B,C). In contrast, complement system activation did not affect FD levels in patients
with BSS (Figure 6B,C). In a previous work, Gaya da Costa et al. showed that FD levels
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were not related to either the activity of the AP or C3 levels in a healthy population [38],
in agreement with our results (Figure 5). In contrast to other AP proteins, FD does not
undergo proteolytic activation to justify its consumption during AP activation. There
are studies about FD levels in systemic lupus erythematosus (SLE), another condition
characterized by pathological activation of the complement system, in which plasma levels
of FD were not different from those of healthy controls [39,40]. Complement activation in
SLE is mainly due to the classical pathway, with limited AP implication, is and normally
not as pronounced as in C3G, which may explain why patients with SLE do not show a
decrease in plasma FD levels. FD is almost completely reabsorbed in the renal tubule, but
in situations where a selective defect of the tubular epithelium occurs, such as Fanconi’s
syndrome, FD levels were elevated in urine and decreased in plasma [36]. C3G is a chronic
disease that tends to progress to end-stage renal disease and tubular atrophy in advanced
cases [41]. C3NeF induces a marked activation of the AP, which usually appears even be-
fore renal manifestations. This chronic activation of the complement system causes massive
production of complement fragments which are deposited in the kidney, severely damag-
ing the organ and leading to tubular dysfunction and renal failure [41]. Defective tubular
reabsorption could therefore explain the lower levels of FD found in C3NeF-positive pa-
tients with C3G. However, further studies are needed to understand whether this is the
case or whether the lower FD levels are mediated by different mechanisms secondary to
complement activation.
In our BSS cohort, three out of thirteen patients (23%) had kidney disease (Table 1),
and all of them showed elevated levels of plasma FD in contrast to those observed in
patients with C3G. Moreover, as we have previously clarified, in patients with BSS, FD
levels do not correlate with the degree of activation of the complement system. Therefore,
one possible explanation of our results is that adipose tissue of patients with BSS expresses
more FD than unaffected adipose tissue, resulting in significantly elevated circulating levels.
To further examine this hypothesis, we studied the presence of FD in the adipose tissue
from the affected arm of an 11-year-old girl with BSS, observing that FD in the atrophied
areas was significantly overrepresented compared to healthy donor tissue (Figure 7A,B).
Although most FD staining was present in the extracellular space and the stroma vascular
cells, some adipocytes showed remarkable cytoplasmic staining (Figure 7A,C). Considering
these results, the stroma vascular fraction could have a determining role in the synthesis
of complement components in the pathogenic context of BSS, but further experiments
will be necessary to confirm this hypothesis. In a previous report from our group, we
demonstrated ongoing complement activation by detecting local C3, C5a, and C5b-9 de-
posits in adipose tissue from this same patient [7]. In this context, if FD production is
higher than usual, further activation of the AP could occur locally in the adipose tissue,
and combined with the presence of C3NeF, damage of the tissue would occur. However,
following mRNA quantification in the patient’s adipose tissue, we observed decreased
CFD and C3 but elevated C5 transcript levels as compared to those from the adipose tissue
of a control female obtained from the same anatomical location (Table 2). Although these
results are somewhat conflicting with respect to those obtained by immunohistochemistry,
they could be explained by the lower expression of PPARG and CEBPA regulatory genes
observed in the patients’ samples, a scenario consistent with lipoatrophy (Table 2) [42]. In
agreement with this, the down-regulation of PPARG may be the main causative event of the
coordinate impairment in the expression of CFD and C3 genes, which are known targets of
PPARG-dependent regulation [43,44]. Correspondingly, if the tissue sample was obtained
at an advanced stage of lipodystrophy, the expression of complement genes may be sig-
nificantly influenced by down-regulation of PPARG and CEBPA. However, the elevated
expression of C5 (Table 2), a gene not controlled by PPARG, may suggest that upregulation
of complement-related genes is a chronic phenomenon occurring before and during adipose
tissue damage. Nevertheless, we cannot rule out that the differences we observed between
the controls and the patient may be due to a lack of age matching. Previous data showed
that C5, but not C3 levels, increase with age [38], and as we demonstrated in this work, FD
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concentration increased with age in controls. According to this higher CFD and C5 mRNA
levels would be expected in controls as compared to the patient. Our finding of reduced
expression of the CFD gene in the patient is in striking contrast to bibliography-based
expectations, but conversely, we observed higher C5 expression in the patient´s tissue,
which could partially support our hypothesis. However, we cannot rule out that the lower
CFD expression in the BSS is a direct consequence of the down-regulation of the PPARG
gene, or that it is due to the lack of appropriately age-matched controls. On the other hand,
our immunohistochemistry results may instead reflect (i) a lack of correlation between FD
and C3 mRNA/protein levels in this pathological context and (ii) the effects of persistent
tissue damage on the adipose tissue, thus providing information on the ongoing pathogenic
process. Moreover, in light of these observations, we cannot rule out the contribution of
other non-adipose cell types to the adipocyte milieu of complement proteins. For these
hypotheses to be tested, fat biopsies from affected and unaffected areas should be obtained
during the progression of the disease, which is a major and evident limitation.
In conclusion, the findings herein presented suggest that FD could be a reliable
diagnostic biomarker involved in the pathophysiology of BSS by promoting unrestrained
local complement system activation in the adipose tissue environment. Further studies are
needed to validate its importance in the mechanism of the disease, as well as a possible
treatment target.
4. Materials and Methods
4.1. Study Cohorts
Thirteen patients with BSS and 20 patients with AGL were enrolled for this study.
All of them were diagnosed based on standardized criteria [45]. Briefly, one criterion
for both lipodystrophies was fat loss during childhood or adulthood. The patients with
BSS were characterized by large areas of the body being affected, particularly the head,
shoulders, upper extremities, and trunk, with preservation of adipose tissue in the lower
extremities. In contrast, patients with AGL were characterized by loss of fat, affecting
the entire body. The presence of autoimmune markers or autoimmune diseases can be
supportive of the diagnosis of BSS and AGL. Laboratory findings such as low complement
C3 and the presence of C3NeF were used during the diagnosis of BSS.
Congenital forms of lipodystrophy were excluded based on the natural history of the
disease, clinical features, age at onset, and/or pathogenic variants in CGL (AGPAT2, BSCL2,
CAV1, PTRF, PPARG) and FPLD-related genes (LMNA, PPARG, PLIN1, CIDEC, LIPE, CAV1,
AKT2). No consanguinity was reported in any case. The clinical, demographical, and
immunological features for these 13 patients with BSS were previously described in [2].
Twenty-two patients with biopsy-proven C3G were selected for inclusion in this study
based on standardized criteria [6,46,47]. Additionally, 50 healthy subjects were recruited
as controls.
All cohorts were matched in terms of sex and age. For more details, see Table 1.
4.2. Biological Samples
Blood samples were drawn in plain tubes, allowed to clot at room temperature, and
centrifuged for 10 min at 4 ◦C. EDTA-plasma was aliquoted and stored at –20 and –80 ◦C
until use to avoid repeated freezing and thawing.
Immunohistochemistry and gene expression studies were performed using subcu-
taneous adipose tissue biopsy from the arm of an 11-year-old girl with BSS (described
in [7]). As controls, we collected subcutaneous adipose tissue from two healthy, lean,
male and female (69- and 57-year-olds, respectively) obtained at similar anatomical sites
(arm). Adipose samples from these healthy controls has been described elsewhere [48].
The tissues used for histological studies were stored in paraffin blocks. Fresh frozen tissues
were preserved until their use to extract mRNA.
Int. J. Mol. Sci. 2021, 22, 6608 11 of 14
4.3. Complement System Determinations
Serum C3 levels were measured by nephelometry (Siemens Healthcare, Erlangen,
Germany). C3NeF was detected by ELISA assay as previously described [49].
4.4. Measurement of FD in Plasma by ELISA
Plasma FD was measured using an in-house ELISA assay, optimized for use in plasma.
ELISA plates (MaxiSorp®, Nunc) were coated with 100 ng/well of mouse monoclonal
anti-human FD (GAU 01-04-02, Invitrogen, Carlsbad, CA, USA) diluted in carbonate-
bicarbonate buffer pH 9.3 (overnight, 4 ◦C). Plates were blocked with PBS-BSA 1% and
washed with PBS-BSA 0.1% (both incubations 1 h at 37 ◦C). A standard curve ranging from
0 to 80 ng/mL of purified FD (Complement Technology, Tyler, TX, USA) was included
on each plate, alongside one internal control plasma sample used to assess interassay
variability. The interassay coefficient of variation was below 10%. Plasma samples were
diluted in PBS-BSA 0.1% at 1/50, 1/100, and 1/200 dilutions for analysis. FD detection was
made using a mouse monoclonal anti-human FD conjugated with biotin (GAU 008-01B-02,
Invitrogen) (1/2500 dilution, 1 h at 37 ◦C) and then with streptavidin-peroxidase polymer
(S2438, Sigma Aldrich, St Louis, MO, USA) (1/400, both incubations 45 min at 37 ◦C).
The reactions were developed using ABTS as substrate and read at 405/620 nm using an
Epoch™ Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA). All
samples were measured in duplicate.
4.5. Western Blot Analysis
Plasma underwent electrophoresis in SDS-PAGE gels and was transferred to nitrocel-
lulose membranes using iBlot 2 Dry Blotting System (Invitrogen). They were incubated
with anti-FD antibody (PA5-79034, Invitrogen) (1/1000 dilution, overnight at 4 ◦C) and
then with goat anti-rabbit IgG (#107-6515, Bio-Rad, Hercules, CA, USA) (1/40,000 dilution,
1 h at room temperature). Peroxidase activity was analyzed using ECL™ Select West-
ern Blotting Detection Reagent (GE Healthcare Bio-Sciences, New Burnswick, NJ, USA).
UVITEC Alliance 1D MAX (UVITEC Cambridge) was used for image acquisition.
4.6. RNA Extraction and qRT-PCR
Adipose tissue samples were fragmented by mechanical disruption and then ho-
mogenized in RA-1 buffer (Macherey-Nagel, Düren, Germany) supplemented with 10%
β-mercaptoethanol. RNA was immediately isolated from the homogenate using a col-
umn affinity-based methodology (NucleoSpin® RNA II; Macherey-Nagel). cDNA was
synthesized from 0.5 µg of total RNA using MultiScribe reverse transcriptase and random
hexamer primers (Applied Biosystems, Foster City, CA, USA). mRNA expression levels
were determined by quantitative real-time reverse transcription-polymerase chain reaction
(qRT-PCR) using TaqMan reagents and an Applied Biosystems 7500 Fast Real-Time PCR
System (Applied Biosystems). Real-time PCR was performed in a final volume of 20 µL
using TaqMan Universal PCR Master Mix, No AmpErase UNG reagent, and the following
specific primer probes (TaqMan Gene Expression Assays; Applied Biosystems): C3 (Com-
plement component 3), Hs00163811_m1; C5 (Complement component 5), Hs01004342_m1;
CFD (Complement factor D, adipsin), Hs00157263_m1; PPARG (peroxisome proliferator-
activated receptor-gamma, PPAR-γ), Hs00234592_m1; CEBPA (CCAAT enhancer-binding
protein-alpha), Hs00269972_s1. Data for mRNA levels of the genes of interest were normal-
ized to that of reference control (18S ribosomal RNA, Hs99999901_s1) and were calculated
using the comparative 2-∆CT method.
4.7. Immunohistochemical Staining
The adipose tissue was sectioned (5 µm) using a rotary paraffin microtome (Leica,
RM2255, Wetzlar, Germany). The sections were placed on IHC Microscope Slides (K8020,
Dako, Santa Clara, CA, USA) and stored until their use. The sample was dewaxed with
xylene and rehydrated with 100, 96, 80, 70% (5 min each) ethanol. After this step, the
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sample was washed in tris-buffered saline (TBS) (150 mM NaCl, 50 mM Tris-HCl, pH 7.6).
The slides were placed into citrate-antigen repairing solution (0.01 M, pH 6.0) and the
unmasking of the epitopes was performed using the PT LINK system (Dako) following
the instructions of the manufacturer. The sample was blocked using TBS supplemented
with 10% goat serum in a wet chamber for 1 h at room temperature. FD was detected
using a polyclonal rabbit anti-human FD (PA5-79034, from Invitrogen) with a dilution of
1 µg/mL (overnight at 4 ◦C in a wet chamber). The color reaction was developed using
the Mouse and Rabbit Specific HRP/DAB (ABC) Detection IHC kit (ab64264, from Abcam,
Cambridge, UK). Staining was performed using a rabbit IgG (ab172730; Abcam) as an
isotype control. Finally, the tissue was counterstained with hematoxylin and mounted with
DPX mounting medium.
4.8. Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 6.01 (San Diego,
CA, USA). Concentrations of complement FD are represented as median with interquartile
range (IQR). Mann–Whitney U and Kruskall–Wallis non-parametric tests were used for
statistical analysis and Spearman Rank correlation coefficient (r) was used for correlation
between variables. Receiver operating characteristic (ROC) curve analysis was used to
analyze the diagnostic value of plasma FD levels as a potential biomarker. Additionally,
other statistical parameters, such as sensitivity, specificity, cut-off value, positive predictive
value, negative predictive value, and area under the ROC curve (AUC) with 95% confidence
interval (CI), were also evaluated. p < 0.05 was considered statistically significant.
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